Welcome to our dedicated page for Biote SEC filings (Ticker: BTMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Biote Corp. (NASDAQ: BTMD) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports, earnings-related materials and other documents filed with the U.S. Securities and Exchange Commission. Biote is a preventive health care solutions provider focused on personalized hormone optimization and therapeutic wellness, and its filings offer detailed insight into this business.
Biote’s filings include Forms 8-K that furnish press releases on quarterly financial results and material events. For example, the company has filed an 8-K to report financial results for the quarter ended September 30, 2025, attaching the full earnings press release as an exhibit. These documents summarize revenue trends, procedure and dietary supplement revenue, gross profit margins, operating income, net income and non-GAAP measures such as Adjusted EBITDA and Adjusted EBITDA margin.
Through its periodic reports, investors can review information on Biote’s revenue mix, cost structure and capital allocation, including references to share repurchase programs and settlement-related share repurchases. The company also explains how it calculates non-GAAP metrics and outlines the limitations of these measures compared with GAAP results.
On Stock Titan, Biote’s SEC filings are supplemented with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand the main drivers of performance, changes in guidance and significant corporate actions. Real-time updates from EDGAR ensure that new 8-Ks and other filings appear promptly, while structured access makes it easier to locate earnings materials and other regulatory disclosures for BTMD.
biote Corp. (BTMD) reported a return to profitability for the quarter ended June 30, 2025 while carrying meaningful leverage and ongoing contingent liabilities. Total revenue for the quarter was $48.9 million (product revenue $47.7M), roughly flat year-over-year, and operating income improved to $10.8 million from $6.2M a year earlier. Net income for the quarter was $3.9 million and net income attributable to Biote stockholders was $3.2 million (basic EPS $0.10), reversing prior-year losses. For the six months, net income was $19.8 million and revenue totaled $97.9 million.
On the balance sheet, cash declined to $19.6 million from $39.3M at year-end and total assets fell to $104.8 million. Total liabilities remained elevated at $183.6 million, leaving a stockholders' deficit attributable to Biote of $85.1 million. The company remains in compliance with its credit covenants on a Term Loan that matures in May 2027. Significant items in the period include a $8.9 million mark-to-market gain on earnout liabilities and settlement activity that reduced share repurchase liabilities following a $25.1M repurchase payment.